TRxADE HEALTH Announces Board Changes and Listing Updates
Ticker: SCNX · Form: 8-K · Filed: May 30, 2024 · CIK: 1382574
| Field | Detail |
|---|---|
| Company | Trxade Health, Inc (SCNX) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: board-changes, listing-rule, officer-compensation
TL;DR
Board shakeup at TRxADE HEALTH, new directors in, potential listing rule issues.
AI Summary
TRxADE HEALTH, INC. filed an 8-K on May 23, 2024, reporting a departure of directors and the election of new ones. The company also disclosed compensatory arrangements for certain officers and provided updates related to its listing status. This filing indicates significant changes in the company's board and potential implications for its stock exchange listing.
Why It Matters
Changes in a company's board of directors and potential listing issues can significantly impact investor confidence and the stock's future trading prospects.
Risk Assessment
Risk Level: medium — The filing mentions potential delisting or failure to meet listing standards, which poses a significant risk to the company's public trading status.
Key Players & Entities
- TRxADE HEALTH, INC. (company) — Registrant
- May 23, 2024 (date) — Earliest event reported
- 0001382574 (company) — Central Index Key
FAQ
What specific reasons were given for the departure of directors?
The filing indicates a departure of directors but does not specify the reasons in the provided text.
Who are the newly elected directors?
The filing mentions the election of directors but does not name the individuals in the provided text.
What are the details of the compensatory arrangements for officers?
The filing notes compensatory arrangements for certain officers but does not provide specific details in the provided text.
What is the nature of the notice regarding the company's listing status?
The filing includes a notice of delisting or failure to satisfy a continued listing rule or standard, indicating potential issues with maintaining its stock exchange listing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 23, 2024.
Filing Stats: 1,489 words · 6 min read · ~5 pages · Grade level 10.3 · Accepted 2024-05-30 16:05:38
Key Financial Figures
- $0.00001 — ch registered Common stock, par value $0.00001 per share MEDS The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex99-1.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-021967.txt ( ) — 243KB
- meds-20240523.xsd (EX-101.SCH) — 3KB
- meds-20240523_lab.xml (EX-101.LAB) — 33KB
- meds-20240523_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRxADE HEALTH, INC. By: /s/ Surendra Ajjarapu Surendra Ajjarapu Chief Executive Officer Date: May 30, 2024